Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Caitlin E. Cox

November 28, 2018

News Daily News

Aspirin Should Play Limited Role in Primary Prevention: Review

Michael O'Riordan

November 27, 2018

News Conference News AHA 2018

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Michael O'Riordan

November 11, 2018

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

News Daily News

Silent Infarcts Have Similar Mortality Over 10 Years as Clinically Recognized MI

Yael L. Maxwell

October 10, 2018

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Todd Neale

October 03, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

VERDICT: Very Early Invasive Angiography No Help Overall for NSTE ACS

Todd Neale

August 29, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Todd Neale

April 24, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

Advertisement

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Aspirin Should Play Limited Role in Primary Prevention: Review

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Silent Infarcts Have Similar Mortality Over 10 Years as Clinically Recognized MI

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

TCTMD’s Top 10 Most Popular Stories for August 2018

VERDICT: Very Early Invasive Angiography No Help Overall for NSTE ACS

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content